Drug intelligence / Profile preview

ABBV-722

Development stage: Phase 1
Lead developer: AbbVie
Modality: Antibody-Based Therapeutics, Small Molecules
Administration: Oral

Overview

ABBV-722 is a lysophosphatidic acid receptor 1 (LPAR1) antagonist antibody being developed by AbbVie for the treatment of systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). LPAR1 is implicated in the pathology of fibrotic diseases, amplifying inflammation and fibrosis in tissues such as the lungs. Inhibition of LPAR1 may help address disease progression in SSc and IPF. The drug is currently undergoing Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics after oral dosing in healthy adult participants.

Other names: ABBV 722ABBV722ABBV-722

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on ABBV-722.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-722.

Explore the full profile